Review Article
The Role of Anticoagulation Clinics in the Era of New Oral Anticoagulants
Table 2
Principal characteristics of new oral anticoagulants ([
18,
19], modified).
| | | Dabigatran | Rivaroxaban | Apixaban | Edoxaban |
| | Target | IIa | Xa | Xa | Xa | | Prodrug | Yes | No | No | No | | Hours to | 2 | 2–4 | 1–3 | 1.5 | | Bioavailability | 7% | 80% | 66% | 50% | | Half-life (hours) | 12–14 | 9–13 | 8–15 | 6–11 | | CYP metabolism | No | Yes | Yes | Yes | | Efflux transporter P-gp | Yes | Yes | Yes | Yes | | Renal elimination | 80% | 66% (33% cleared unchanged) | 25% | 35% | | Dosing | Bid | Od | Bid | Od |
|
|
